In-silico clinical trials
Prove it on virtual patients first
Sanenza simulates a drug across a realistic synthetic population, so dose, cohort and endpoint choices are tested before the first real patient is enrolled.
Sanenza is pre-launch and is looking for design partners for 2027 pilots.
- Responder
- Adverse event
- No response
- Rare subgroup
Move the dose to see the trade-off a dose-finding study has to settle.
Design targets
What we are building toward
These are targets the pilot programme will measure. They are goals, not results.
Design target for one simulated arm.
Candidate designs Protova aims to compare per question.
Target for a dose sweep that takes weeks on CPU solvers.
From data agreement to a back-tested report.
The problem
Trials fail on choices made too early
Most of a programme's cost is committed when the protocol is fixed. Dose, cohort and endpoints are chosen from thin, biased history, and a wrong choice shows up years later.
Dose
Picked from a handful of scenarios
Classical PK-PD and QSP models are accurate but slow, so teams explore a few doses instead of the full range.
Cohort
Built on data that misses people
Paediatric, rare-disease and under-represented groups are barely present in historical trials, so their risk stays unknown.
Safety
Rare events surface too late
An adverse event that affects one patient in a thousand rarely appears in a trial of three hundred.
Six products, one virtual patient
From population to evidence in one loop
Every product reads the same virtual patients and writes to the same validation ledger, so each programme improves the next one.
- 01PopulateCohorta
Generates calibrated virtual-patient cohorts for an indication, region or rare subgroup.
- 02SimulateInsilon
Runs the compound across the whole cohort with PK-PD surrogates and biomolecular response.
- 03DesignProtova
Searches dose, cohort, endpoint and sample size, and scores every candidate protocol.
- 04Stress-testVigila
Oversamples rare subgroups to find adverse-event signals before a patient is exposed.
- 05LocalisePhysova
Renders organ-scale twins for tissue exposure and drug-device questions.
- 06ValidateEvidra
Links each prediction to the real outcome and sends recalibration back to every product.
How it works
A simulated trial in four steps
Week 1
Define the question
Pick the compound, indication and decision: dose, cohort, endpoint or sample size.
Week 2–3
Build the population
Cohorta generates a calibrated cohort from physiology priors and omic and EHR variability.
Week 4–7
Simulate and search
Insilon runs every candidate arm; Protova scores designs on power, efficacy, safety and equity.
Week 8–10
Validate and report
Evidra back-tests against known outcomes and writes an auditable evidence package.
Who it's for
Built for the teams who sign off the protocol
MIDD
Clinical pharmacology
Population-scale exposure and response to support dose selection.
Read moreDesign
Clinical development
Ranked protocols with the trade-offs written down.
Read moreSafety
Drug safety and PV
Rare-subgroup stress tests before first-in-human and after launch.
Read morePartners
CROs and academic centres
Simulation capacity for sponsor studies and research.
Read moreTechnology
Mechanistic models at GPU speed
Each virtual patient is a coupled physiology and molecular system. Running tens of thousands of them per arm needs accelerated compute.
For developers
One API from cohort to evidence
Create cohorts, start simulation runs and pull results into R, Python or SAS. Every run gets an Evidra record, so results stay traceable.
- REST API and Python client, versioned
- Each result carries its cohort version, model version and seed
- CDISC-aligned exports for downstream analysis
# Simulate two doses across a Cohorta population curl -X POST "https://api.sanenza.com/v1/runs" \ -H "Authorization: Bearer $SANENZA_TOKEN" \ -d '{ "cohort": "chr-nsclc-eu-v3", "compound": "SZ-0412", "arms": [{ "dose_mg": 20 }, { "dose_mg": 40 }], "patients_per_arm": 10000, "outputs": ["orr", "grade3_ae", "exposure_auc"] }' # Response (abridged, example values) { "run": "run_7f3a", "status": "queued", "evidra_record": "ev_20a1" }
Questions
Common questions
Is Sanenza available today?
Not yet. Sanenza is pre-launch. We are working with a small number of design partners on 10-week pilots that start in 2027.
Does in-silico evidence replace clinical trials?
No. Simulation helps choose better doses, cohorts and endpoints, and can support model-informed drug development. Physical trials and regulatory review remain the decision point.
Do regulators accept this evidence?
Acceptance of in-silico evidence is evolving and depends on the question and therapeutic area. Sanenza produces documented, back-tested evidence for your MIDD work; it does not guarantee acceptance.
Where does the patient data come from?
From your own trial and real-world data under your agreements, plus licensed and public sources. Protected health data is processed in confidential-computing environments.
Test your next protocol on virtual patients
Start with a briefing: a Sanenza scientist walks your trial team through a back-test on a public example, then we look at one open question from your programme.